Skip to main content
OpenTrials
Recruiting

NCT Number: NCT05670262

The Roles of Human Microbiome and Vitamin D in the Development of Childhood Allergic Diseases

A birth cohort study to evaluate the role of human microbiome and vitamin D in the development of allergic diseases in young child before one year of age.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

0 year–1 year

Sex eligibility

All sexes

Study type

Observational

Primary location

China Medical University Hospital

Taichung, 404, Taiwan

Location status: Recruiting

Location contact

Jiu-Yao Wang, MD

CONTACT

[email protected]

886422052121 ext. 4131

About this study

Allergic diseases are chronic inflammatory disorders that frequently affect young infants before one year of age, and is the beginning of allergy march in later life. The prevalence is increasing in industrial world, Taiwan included. Genetic and environmental factors, such exposure to allergens and microbes, especially early in life, have a detrimental role in the development of allergic diseases, such as atopic dermatitis (AD), allergic rhinitis and asthma. Vitamin D has an important role in different allergic disease. Lower cord blood vitamin D status was observed in infants that developed eczema. Vitamin D binding protein (DBP) bound to vitamin D and regulated its metabolites in the circulation. Moreover, vitamin D receptors have been identified on nearly all cells of the immune system. It may contribute to maintenance of intestinal barrier function by preventing increased intestinal permeability, dysbiosis, inflammation, and a lack of immune tolerance in the gut.

Although aberrant interactions between gut microbes and the intestinal immune system have been implicated in this allergic disease, however, the causal effect of microbiota colonization of the gut and vitamin D that influence the development of allergic diseases, such as AD, in young infants is still unknown. The investigators plan to design a birth cohort study to evaluate the role of human microbiome and vitamin D in the development of allergic diseases in young child before one year of age.

In this study, the investigators will recruit mother-infant pairs in antenatal clinics in China Medical University Hospital and China Medical University Children's Hospital. Newborns who have been enrolled at birth are collected for meconium samples before discharged from nursery and eligible for follow-up visits, and collect their nasal and anal swab microbiome samples at 2 and 12 months follow-up visit. Parental questionnaires are collected at 6, and 12 months of age. All infants were assessed at birth, 2 and 6, and 12 months of age. Assessment included physical examination for allergic diseases. In addition, infants at 12 months of age were collected their 3cc of blood sample.

The investigators believe this longitudinal and prospective study, to follow-up infants from the date of birth until one years old, can answer the cause-effect relationships of microbiota and vitamin D in the development of allergic diseases, and design a microbiota-related preventive and treatment strategy.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • All term newborn babies who are born in China Medical University Hospital. The term baby defines the maternal gestational age between 37 0/7 weeks to 41 6/7 weeks.

Exclusion criteria

  • The exclusion criteria are prematurity newborn, congenital anomalies and cardiopulmonary failure need for resuscitation immediately after birth.

Treatment and study plan

Primary outcomes

  1. Microbiome

    Time frame: Month 0

    Meconium samples will be used to detect intestinal microbiome by using 16S rRNA sequencing to determine baseline status.

  2. Microbiome

    Time frame: Month 2

    Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing to determine baseline status.

  3. Microbiome

    Time frame: Month 12

    Nasal and anal swabs will be used to detect respiratory and intestinal microbiome by using 16S rRNA sequencing,and to follow the change from baseline in microbiome at month 12.

  4. Levels of vitamin D

    Time frame: Month 12

    Vitamin D will be measured in a blood sample by ELISA.

  5. Single nucleotide polymorphism of vitamin D receptor and vitamin D binding protein

    Time frame: Month 12

    Single nucleotide polymorphism (SNP) genotyping will be performed in a blood sample by using TaqMan SNP genotyping assays.

  6. Total immunoglobulin E (IgE)

    Time frame: Month 12

    Plasma total IgE concentration will be measured by microparticle immunoassay (IMx analyzer, Abbott Laboratories, Abbott Park, IL) and ELISA.

  7. Allergen-specific immunoglobulin E (IgE)

    Time frame: Month 12

    Plasma allergen-specific IgE will be measured by BioIC ®.

Secondary outcomes

  1. Parental questionnaire (0-6 month)

    Time frame: Month 6

    For assessing child's health, feeding habit, and environmental exposure

  2. Parental questionnaire (6-12 month)

    Time frame: Month 12

    For assessing child's health, feeding habit, and environmental exposure

Study contacts

Contact information is provided by the study sponsor or research team.

Jiu-Yao Wang, MD

CONTACT

[email protected]

886422052121 ext. 4131

Sponsors and collaborators

Lead sponsor

China Medical University Hospital

Other

Registry information

Important dates

Study start
2022
Primary completion
2027
Study completion
2027
First posted
Jan 4, 2023
Registry last updated
Feb 7, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.